{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T23:57:42Z","timestamp":1773446262112,"version":"3.50.1"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The molecular characterization of patient tumors provides a rational and highly promising approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic medicine still remains in its infancy, with innovators and early adopters continuing to carry a significant portion of the clinical and financial risk. Numerous innovative precision oncology trials have emerged globally to address the associated need for evidence of clinical utility. These studies seek to capitalize on the power of predictive biomarkers and\/or treatment decision support analytics, to expeditiously and cost-effectively demonstrate the positive impact of these technologies on drug resistance\/response, patient survival, and\/or quality of life. Here, we discuss the molecular foundations of these approaches and highlight the diversity of innovative trial strategies that are capitalizing on this emergent knowledge. We conclude that, as increasing volumes of clinico-molecular outcomes data become available, in future, we will begin to transition away from expert systems for treatment decision support (TDS), towards the power of AI-assisted TDS\u2014an evolution that may truly revolutionize the nature and success of cancer patient care.<\/jats:p>","DOI":"10.3390\/jpm9030043","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T02:59:22Z","timestamp":1567738762000},"page":"43","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Precision Oncology\u2014The Quest for Evidence"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6051-6605","authenticated-orcid":false,"given":"Theodoros","family":"Soldatos","sequence":"first","affiliation":[{"name":"Molecular Health GmbH, 69115 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajo","family":"Kaduthanam","sequence":"additional","affiliation":[{"name":"Molecular Health GmbH, 69115 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jackson","sequence":"additional","affiliation":[{"name":"Molecular Health GmbH, 69115 Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/emmm.201100176","article-title":"Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: Promises and perils","volume":"3","author":"Torti","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"ref_2","unstructured":"Food & Drug Administration (FDA) (2019, August 07). Table of Pharmacogenomic Biomarkers in Drug Labeling, Available online: http:\/\/www.fda.gov\/drugs\/science-research-drugs\/table-pharmacogenomic-biomarkers-drug-labeling."},{"key":"ref_3","unstructured":"Food & Drug Administration (FDA) (2019, August 07). Table of Pharmacogenomic Biomarkers in Drug Labeling, Available online: https:\/\/www.fda.gov\/media\/124784\/download."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11523-018-0590-1","article-title":"TRK Inhibition: A New Tumor-Agnostic Treatment Strategy","volume":"13","author":"Kummar","year":"2018","journal-title":"Target. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Nicolas, E., Bertucci, F., Sabatier, R., and Gon\u00e7alves, A. (2018). Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. Cancers (Basel), 10.","DOI":"10.3390\/cancers10120506"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1200\/JCO.2008.21.3744","article-title":"Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab","volume":"27","author":"Jacobs","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","article-title":"Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells","volume":"65","author":"Nahta","year":"2005","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1158\/1078-0432.CCR-06-1304","article-title":"Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer","volume":"13","author":"Harris","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","article-title":"American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy","volume":"27","author":"Allegra","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/sj.bjc.6604009","article-title":"PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients","volume":"97","author":"Frattini","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.3748\/wjg.v16.i46.5881","article-title":"Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer","volume":"16","author":"Li","year":"2010","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41746-019-0148-3","article-title":"Artificial intelligence and machine learning in clinical development: A translational perspective","volume":"2","author":"Shah","year":"2019","journal-title":"NPJ Digit. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1017\/S026646231800048X","article-title":"Evidence Required by Health Technolgy Assessment and Reimbursement Bodies Evaluating Diagnostic or Prognostic Algorithms That Include Omics Data","volume":"34","author":"Barna","year":"2018","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2018.12.003","article-title":"New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology","volume":"73","author":"Janiaud","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S1470-2045(15)00396-4","article-title":"Research methods to change clinical practice for patients with rare cancers","volume":"17","author":"Billingham","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jamaoncol.2016.5299","article-title":"Novel Precision Medicine Trial Designs: Umbrellas and Baskets","volume":"3","author":"West","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2015.66.0084","article-title":"The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non\u2013Small-Cell Lung Cancer","volume":"34","author":"Papadimitrakopoulou","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21037\/atm.2016.11.48","article-title":"Lessons learned from BATTLE-2 in the war on cancer: The use of Bayesian method in clinical trial design","volume":"4","author":"Kim","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1200\/JCO.2009.26.5983","article-title":"Pilot study using molecular profiling of patients\u2019 tumors to find potential targets and select treatments for their refractory cancers","volume":"28","author":"Stephenson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00002","article-title":"Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study","volume":"1","author":"Tsimberidou","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.currproblcancer.2017.02.002","article-title":"Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine","volume":"41","author":"Tsimberidou","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): A multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Delord","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mullard, A. (2015). Use of personalized cancer drugs runs ahead of the science. Nat. News.","DOI":"10.1038\/nature.2015.18389"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e16214","DOI":"10.1200\/JCO.2018.36.15_suppl.e16214","article-title":"Applying evidence-based software for NGS in pancreatic cancer: First results from the PePaCaKa study","volume":"36","author":"Loehr","year":"2018","journal-title":"JCO"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.csbj.2019.03.012","article-title":"Treatment According to Molecular Profiling in Relapsed\/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies","volume":"17","author":"Zimmer","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_39","unstructured":"(2018, December 20). Home Page-FP7-Research-Europa. Available online: https:\/\/ec.europa.eu\/research\/fp7\/index_en.cfm."},{"key":"ref_40","unstructured":"Homepage (2018, December 20). IMI Innovative Medicines Initiative. Available online: http:\/\/www.imi.europa.eu\/."},{"key":"ref_41","unstructured":"Cancer Core Europe (2018, December 20). Cancer Core Europe. Available online: https:\/\/www.cancercoreeurope.eu\/."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/9\/3\/43\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:17:15Z","timestamp":1760188635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/9\/3\/43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["jpm9030043"],"URL":"https:\/\/doi.org\/10.3390\/jpm9030043","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]}}}